Evolus (EOLS) Cash from Financing Activities (2017 - 2026)
Evolus (EOLS) posted Cash from Financing Activities of $7.6 million for Q1 2026, up 9794.81% on a QoQ basis from $77000.0 in Q4 2025, and up 567.14% year-over-year from $1.1 million in Q1 2025.
Evolus (EOLS) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Evolus' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $7.6 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 567.14% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.6 million (up 21872.73% YoY) and the FY2025 annual result came in at $17.3 million, down 63.43% from the prior year.
- Cash from Financing Activities was $7.6 million for Q1 2026 at Evolus, up from $77000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $45.7 million in Q1 2024 and bottomed at -$1.8 million in Q3 2025.
- A 5-year average of $6.6 million and a median of -$849000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 109.3% — and 2024, when it surged 3661.78%.
- Evolus' Cash from Financing Activities stood at -$1.5 million in 2022, then jumped by 1651.58% to $23.5 million in 2023, then tumbled by 105.58% to -$1.3 million in 2024, then jumped by 105.86% to $77000.0 in 2025, then surged by 9794.81% to $7.6 million in 2026.
- Business Quant data shows EOLS's Cash from Financing Activities at $7.6 million in Q1 2026, $77000.0 in Q4 2025, and -$1.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | 7.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.62 Mn |
| Mar 31, 2026 | 7.62 Mn |
| Dec 31, 2025 | 77,000.00 |
| Dec 31, 2025 | 77,000.00 |
| Sep 30, 2025 | -1.77 Mn |
| Sep 30, 2025 | -1.77 Mn |
| Jun 30, 2025 | 20.66 Mn |
| Jun 30, 2025 | 20.66 Mn |
| Mar 31, 2025 | -1.63 Mn |
| Mar 31, 2025 | -1.63 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Jun 30, 2024 | 4.48 Mn |
| Jun 30, 2024 | 4.48 Mn |
| Mar 31, 2024 | 45.66 Mn |
| Mar 31, 2024 | 45.66 Mn |
| Dec 31, 2023 | 23.52 Mn |
| Dec 31, 2023 | 23.52 Mn |